ArticleArthritis care & research2025
Prevalence and Incidence of Sjögren's Disease in Alaska Native and American Indian Peoples of Alaska.
Article in Arthritis care & research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveOur objective was to determine the prevalence, incidence, and clinical characteristics of Sjögren's disease (SjD) in Alaska Native and American Indian (AN/AI) peoples of Alaska.
methodsWe identified adults with SjD by querying electronic health records from participating tribal health organizations within the Alaska Tribal Health System (ATHS). Medical records were abstracted for adults with diagnostic codes for SjD. Individuals were included if they were diagnosed with SjD by a rheumatologist. Prevalence and incidence were calculated using the ATHS user population in 2019 (point prevalence) and from 2012 to 2019 (incidence), with direct age adjustment to the 2000 standard US population. We evaluated whether adults met modified criteria (positive Ro/SSA antigen with sicca symptoms), 2016 American College of Rheumatology (ACR)/EULAR, and 2012 ACR criteria.
resultsThe age-adjusted prevalence of SjD was 199 per 100,000 adults (95% confidence interval [CI] 170-231); for primary SjD, it was 129 (106, 155), and for secondary SjD, it was 70 (95% CI 54-91). The age-adjusted incidence over the period was 16.6 (95% CI 13.7-20.0) per 100,000 person-years. Two-thirds (66%) of adults met modified criteria. Only 5% had a salivary gland biopsy performed, and only 3% met the 2016 ACR/EULAR or 2012 ACR criteria. The most common associated conditions in secondary SjD were rheumatoid arthritis and systemic lupus erythematosus.
conclusionThe prevalence and incidence of SjD in AN/AI peoples is higher than other populations. These results may help clinicians to identify and treat this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.